A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs IMR 687 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Imara Inc
- 11 Oct 2018 According to an Imara Inc media release, a review of this trial will be presented at the Sickle Cell Disease Association of America's (SCDAA) 46th Annual National Convention.
- 13 Feb 2018 According to an Imara media release, first patient has been dosed in this study.
- 09 Jan 2018 Status changed from planning to recruiting.